Welcome to our dedicated page for Tivic Health Systems news (Ticker: TIVC), a resource for investors and traders seeking the latest updates and insights on Tivic Health Systems stock.
Tivic Health Systems, Inc. (NASDAQ: TIVC) is a pioneering health technology company dedicated to transforming bioelectronic medicine. Our core mission is to develop and commercialize non-invasive products that activate the body’s natural healing mechanisms. Headquartered in San Francisco, Tivic Health is at the forefront of delivering innovative solutions for therapeutic benefit, predominantly focusing on sinus pain relief.
Our flagship product, ClearUP Sinus Relief, is a patented handheld device designed to alleviate sinus pain and congestion using ultra-low electrical currents. This device offers a natural alternative to conventional treatments like nasal sprays, pills, and saline flushes, and is particularly beneficial for individuals suffering from nasal allergies, sinus infections, chronic sinusitis, and the common cold.
Our latest innovation, Synus, provides temporary relief from sinus pain and pressure through microcurrents. This product represents our commitment to offering non-pharmaceutical options to those seeking effective and convenient sinus pain management.
With an emphasis on safety and efficacy, Tivic Health is not only advancing bioelectronic medicine but also setting new standards in patient care. Our team of dedicated professionals continually explores the therapeutic potential of microcurrents, aiming to expand our product line to treat various medical conditions in the future. We are committed to enhancing the quality of life for our users by providing accessible and effective health solutions.
For the latest updates and developments, stay tuned to our Latest News section and follow our progress as we continue to innovate and grow in the exciting field of bioelectronic medicine.
Tivic Health Systems, Inc. (TIVC) reported a 72% revenue increase in Q3 2022, totaling $477,000, driven by a 130% rise in direct-to-consumer unit sales. Year-to-date revenue increased 65% to $1.4 million, with gross margins improving 22%. The company announced a $33.5 million acquisition of Reliefband Technologies to expand its product offerings, alongside a partnership with Microart Services to reduce manufacturing costs. However, research and development expenses rose significantly, contributing to a net loss of $2.6 million for the quarter.
Tivic Health Systems, Inc. (TIVC) announced it has entered a non-exclusive manufacturing agreement with Microart Services Inc. This partnership aims to significantly reduce product manufacturing and shipping costs. COO Ryan Sabia emphasized that the agreement offers advantageous pricing and enhances scalability while maintaining North American-based production. Tivic Health focuses on bioelectronic medicine, delivering non-invasive treatments for inflammation and related conditions.
Tivic Health, a health technology company focused on bioelectronic medicine, will showcase its FDA-approved ClearUP device at HLTH from November 13-16 in Las Vegas. ClearUP treats sinus pain and congestion caused by colds and allergies. Recently, Tivic announced a definitive agreement to acquire the Reliefband product line for nausea treatment, integrating wearable FDA-cleared therapeutics. The firm aims to enhance consumer awareness of bioelectronic therapies, backed by clinical studies indicating significant symptom reduction.
Tivic Health Systems, a commercial-phase health technology company, is set to announce its third-quarter 2022 financial results via conference call and webcast on November 14, 2022, at 1:30 PM PT.
Shareholders can submit questions until 5:00 PM ET on November 11, 2022. The company specializes in non-invasive bioelectronic treatments aimed at inflammation and related conditions. For more details, visit Tivic Health.
Tivic Health Systems (Nasdaq: TIVC), a leader in bioelectronic medicine, announced that CEO Jennifer Ernst will present at The ThinkEquity Conference on October 26, 2022, in New York City. This event marks a significant opportunity for the company to showcase its innovative, non-invasive treatments for inflammation and related conditions.
The conference will take place at the Mandarin Oriental Hotel, providing a platform for industry insights and networking.
Tivic Health Systems (NASDAQ: TIVC) has announced a definitive agreement to acquire the Reliefband product line, expanding its portfolio in the bioelectronic treatment of nausea. The deal, valued at up to $33.5 million, aims to leverage Reliefband's FDA-cleared products, which cater to a growing market projected at $2.4 billion in the US. This acquisition is anticipated to increase revenue opportunities significantly, combining direct-to-consumer sales with clinical applications.
Tivic Health Systems (Nasdaq: TIVC) announced that CEO Jennifer Ernst will present at the Fifth Bioelectronic Medicine Summit on October 11-12, 2022 in Garden City, NY. The summit will focus on the commercialization journey of neurotechnology. The conference aims to spotlight bioelectronic medicine's role in healthcare advancements, with discussions regarding current challenges and future developments. Tivic Health is a health technology company specializing in non-invasive bioelectronic treatments for inflammation and related conditions.
Tivic Health Systems, a commercial-phase health technology company focused on bioelectronic medicine, announced that CEO Jennifer Ernst will present at the 148th National Investment Banking Association (NIBA) conference. The event is set to take place on September 7-8, 2022, at Margaritaville Beach Resort, Hollywood, FL. NIBA has significantly impacted the micro-cap investment community since 1982, raising over $30 billion and facilitating around 90% of IPOs valued under $20 million. Tivic Health develops non-invasive treatments for inflammation-related conditions.
Tivic Health (TIVC) reported remarkable financial results for Q2 2022, posting a 97% revenue increase to $528,000 compared to $268,000 in Q2 2021. The company achieved a stunning 265% growth in unit sales via direct-to-consumer channels. Despite rising costs, the average sales cost decreased from $97.18 to $90.26. R&D expenses rose to $497,000 due to team expansions, while sales and marketing expenditures surged to $1.1 million, reflecting strategic investments. However, these developments led to a net loss of $3 million, worsening from $1.1 million in the same quarter last year.
Tivic Health® Systems, Inc. (Nasdaq: TIVC), a health technology firm focused on bioelectronic medicine, will report its financial results for Q2 2022 on August 15, 2022. The earnings call will begin at 1:30 PM PT / 4:30 PM ET, with a conference call for investors and analysts available via toll-free and international lines. Shareholders can also submit questions by August 11, 2022, at ir@tivichealth.com. More information can be found at Tivic Health's website.
FAQ
What is the current stock price of Tivic Health Systems (TIVC)?
What is the market cap of Tivic Health Systems (TIVC)?
What is Tivic Health Systems, Inc.?
What does Tivic Health specialize in?
What is the ClearUP Sinus Relief device?
How does Tivic Health's technology work?
What conditions does ClearUP Sinus Relief treat?
What is Synus?
How is Tivic Health different from pharmaceutical companies?
Where can I learn more about Tivic Health's products?
Why choose Tivic Health products?
What are the future plans for Tivic Health?
